Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Mounjaro and Wegovy are two of the most talked-about weight loss medications in 2026. Despite frequent comparison, they are actually different drugs — here is a clear breakdown.
First: The Naming Confusion
Both drugs come in two branded versions depending on indication. Tirzepatide is branded as Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). Semaglutide is branded as Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). When people compare “Mounjaro vs Wegovy,” they are typically comparing tirzepatide and semaglutide for weight loss purposes.
Mechanism of Action
Wegovy (semaglutide): GLP-1 receptor agonist. Mimics the GLP-1 incretin hormone to suppress appetite, slow gastric emptying, and improve insulin secretion.
Mounjaro/Zepbound (tirzepatide): Dual GIP + GLP-1 receptor agonist. Activates both incretin pathways simultaneously. The GIP component may contribute additional appetite suppression and metabolic effects beyond GLP-1 alone.
Weight Loss Comparison
| Factor | Wegovy (sema 2.4mg) | Zepbound (tirz 15mg) |
|---|---|---|
| Trial weight loss | ~15% body weight | ~20–22% body weight |
| Brand cost (monthly) | $900–$1,300 | $900–$1,300 |
| Compounded available? | Yes — $149–$299/mo | Very limited |
| Years of real-world data | More (since 2017) | Newer (2022+) |
| Weekly injection | ✅ Yes | ✅ Yes |
Side Effects — How Do They Compare?
Both share the same GI-dominated side effect profile: nausea, vomiting, diarrhoea, constipation — most common during dose escalation. Overall tolerability is similar. Some clinicians report tirzepatide causes slightly more nausea at high doses for sensitive patients; others report the opposite. Individual response varies considerably and cannot be predicted in advance.
Which Should You Choose?
Choose Wegovy/semaglutide if: cost or insurance access is a constraint (compounded semaglutide is far more accessible), you want the more established long-term safety record, or your physician recommends it based on your profile.
Choose Mounjaro/Zepbound if: your insurance covers it, you want to maximise weight loss potential, you have not responded sufficiently to semaglutide, or your physician specifically recommends tirzepatide for your metabolic situation.
The Practical Reality
For most people without comprehensive insurance, the choice is effectively made by cost: compounded semaglutide at $149–$299/month vs brand tirzepatide at $900–$1,300/month. The marginal extra weight loss of tirzepatide rarely justifies 4–8x the price when the alternative is highly effective and increasingly accessible.
📖 Further Reading
Frequently Asked Questions
Q: Is Mounjaro or Wegovy more effective?
A: Mounjaro’s counterpart for weight loss, Zepbound (tirzepatide), produces slightly more weight loss on average — about 20–22% body weight vs 15% for Wegovy (semaglutide) at maximum doses. The SURMOUNT-5 trial showed tirzepatide produced approximately 47% more relative weight loss than semaglutide.
Q: Can you switch from Wegovy to Mounjaro?
A: Yes, under physician supervision. Some patients switch after plateauing on semaglutide. Your doctor will guide the transition dosing. Note that tirzepatide brand medications are significantly more expensive, and compounded tirzepatide has far less availability than compounded semaglutide.
Q: Which is cheaper — Mounjaro or Wegovy?
A: Brand prices are similar ($900–$1,300/month). However, compounded semaglutide (the active ingredient in Wegovy/Ozempic) is widely available from telehealth platforms from $149/month. Compounded tirzepatide (Mounjaro/Zepbound active ingredient) has much more limited availability and typically costs more. For most people without insurance, semaglutide wins on cost.
Can’t Afford Brand-Name? Compounded Semaglutide From $149/Month
The most accessible GLP-1 option — physician-supervised, shipped to your door. No insurance needed.
Sponsored | Affiliate link
Affiliate disclosure: This article contains affiliate links. See our Affiliate Disclosure.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.